2023-07-25 08:20:12 ET
- FibroGen ( NASDAQ: FGEN ) appoints Thane Wettig as the company’s interim CEO effective as of July 23, 2023.
- Mr. Wettig has served as FibroGen’s chief commercial officer and a key member of the senior leadership team since June 2020.
- Mr. Wettig succeeds CEO Enrique Conterno, who resigned due to personal reasons, to support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period.
- Mr. Wettig, who has served as the company’s chief commercial officer since June 2020, has more than 30 years of global biopharmaceutical leadership and commercial experience.
For further details see:
FibroGen gets an interim CEO